EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer

Julián Córdoba Sánchez, Inés Monge-Escartín, Javier Gil, Cristina Carrera iD, Joaquín Sáez-Peñataro, Laura Ferrer, Caterina Aversa, Begoña Mellado, Joel Mases, Maria Jose Ribal, Antonio Alcaraz, Antoni Vilaseca iD

The Prostate · 2024

DOI: 10.1002/pros.24755 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Prostate, 2024. Verfasst von Julián Córdoba Sánchez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Uro-Oncology Unit, Hospital Clínic de, Barcelona, Spain. Hauptthemen laut MEDLINE: Thiohydantoins, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To analyse the adverse events (AEs) associated with apalutamide and the impact of a multidisciplinary team (MDT) protocol on its management at a tertiary care hospital in a real‐world setting.

Methods

This was an observational, prospective, cohort study based on real‐world evidence at the Hospital Clínic de Barcelona. Includes patients diagnosed with metastatic hormone‐sensitive prostate cancer (mHSPC) or high‐risk nonmetastatic castration‐resistant prostate cancer (nmCRPC) and who started treatment with apalutamide between May 2019 and March 2023 in a real‐world clinical setting.

Results

Of the 121 patients treated with apalutamide, 52.1% experienced an AE, 19.8% experienced temporarily interruption or a reduction in the dose of apalutamide, and 13.2% discontinued treatment due to AEs. Without MDT protocol (49 patients), 24.5% of patients had to temporarily interrupt or reduce the dose of apalutamide due to AEs, with a median time from the start of treatment of 10.1 months, and 24.5% discontinued apalutamide due to AEs, with a median time from the start of treatment of 3.1 months. Meanwhile, whit MDT protocol (72 patients), 16.7% of patients had to temporarily interrupt or reduce the dose of apalutamide due to AEs, with a median time from the start of treatment of 1.6 months, and 5.6% discontinued apalutamide due to AEs, with a median time from the start of treatment of 4 months. The risk reduction associated with treatment discontinuation was statistically significant ( p‐ value = 0.003).

Conclusions

This study highlights the importance of MDT management of AEs associated with apalutamide to reduce treatment discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiohydantoinsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleAgedProspective StudiesMiddle AgedPatient Care TeamAged, 80 and overCohort StudiesAntineoplastic Agents

Stichwörter der Autor:innen

adverse eventsapalutamidedrug‐drug interactionsmultidisciplinary team managementprostate cancerreal‐world evidence

Substanzen

apalutamideThiohydantoinsAntineoplastic Agents

Autor:innen und Institutionen

  • Uro-Oncology Unit, Hospital Clínic de, Barcelona, Spain.
  • Pharmacy Department, Hospital Clínic de, Barcelona, Spain.
  • Dermatology Department, Hospital Clínic de, Barcelona, Spain.
  • Clinical Pharmacology Department, Hospital Clínic de, Barcelona, Spain.
  • Medical Oncology Department, Hospital Clínic de, Barcelona, Spain.
  • Radiotherapy Oncology Department, Hospital Clínic de, Barcelona, Spain.

ORCID-Profile: Cristina Carrera, Antoni Vilaseca

Zitieren

APA

Córdoba Sánchez, J., Monge-Escartín, I., Gil, J., Carrera, C., Sáez-Peñataro, J., Ferrer, L., Aversa, C., Mellado, B., Mases, J., Ribal, M. J., Alcaraz, A., & Vilaseca, A. (2024). Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer. The Prostate. https://doi.org/10.1002/pros.24755

Vancouver

Córdoba Sánchez J, Monge-Escartín I, Gil J, Carrera C, Sáez-Peñataro J, Ferrer L, et al. Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer. The Prostate. 2024. doi:10.1002/pros.24755

BibTeX
@article{CrdobaSnchez2024,
  author = {Córdoba Sánchez, Julián and Monge-Escartín, Inés and Gil, Javier and Carrera, Cristina and Sáez-Peñataro, Joaquín and Ferrer, Laura and Aversa, Caterina and Mellado, Begoña and Mases, Joel and Ribal, Maria Jose and Alcaraz, Antonio and Vilaseca, Antoni},
  title = {Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24755}
}
Kostenlos starten →